Thursday, April 13th, 2023

7:30am - 9am

In-Person NC8.212

Talk Title: Elacestrant (Oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negactive Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial"

Speaker: Dr. Ethan Tobias

Session date: 
04/13/2023 - 7:30am to 9:00am CDT
Location: 
UT Southwestern Medical Center North Campus
Dallas, TX 75390
United States
See map: Google Maps
Add to calendar: 
  • 1.50 AMA
  • 1.50 Attendance
Please login or create an account to take this course.
Faculty List: 
Committee member(s)

Monika Kumar, MD

has no relevant financial relationships to disclose at this time.
Course Director(s)

Amy Jones, M.D.

has no relevant financial relationships to disclose at this time.
Speaker(s)

Ethan Tobias, MD

has no relevant financial relationships to disclose at this time.